Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells 5,000 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, January 13th. The stock was sold at an average price of $87.86, for a total transaction of $439,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Wednesday, December 15th, Jean Jacques Bienaime sold 6,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.71, for a total transaction of $496,260.00.
  • On Wednesday, December 1st, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $87.22, for a total value of $130,830.00.

Shares of NASDAQ BMRN opened at $90.22 on Friday. The stock has a market capitalization of $16.56 billion, a PE ratio of 1,127.75, a P/E/G ratio of 2.90 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 4.49 and a debt-to-equity ratio of 0.25. The firm has a fifty day moving average of $86.24 and a 200-day moving average of $81.34. BioMarin Pharmaceutical Inc. has a 52-week low of $71.59 and a 52-week high of $92.17.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Tuesday, October 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. The company had revenue of $408.74 million during the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a net margin of 0.86% and a return on equity of 2.02%. BioMarin Pharmaceutical’s revenue for the quarter was down 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 earnings per share. Equities research analysts expect that BioMarin Pharmaceutical Inc. will post 0.29 EPS for the current fiscal year.

Several analysts have commented on BMRN shares. SVB Leerink reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Thursday, December 2nd. Credit Suisse Group upped their price objective on shares of BioMarin Pharmaceutical from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, November 22nd. Wedbush reiterated an “outperform” rating and set a $152.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, October 28th. Piper Sandler raised their price objective on shares of BioMarin Pharmaceutical from $119.00 to $121.00 and gave the company an “overweight” rating in a research report on Thursday, October 28th. Finally, Guggenheim boosted their target price on BioMarin Pharmaceutical from $103.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, November 22nd. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $110.76.

Several hedge funds have recently made changes to their positions in the company. Spire Wealth Management boosted its holdings in BioMarin Pharmaceutical by 59.7% in the fourth quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 141 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of BioMarin Pharmaceutical by 0.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 31,626 shares of the biotechnology company’s stock valued at $2,638,000 after buying an additional 156 shares during the last quarter. Bbva USA grew its position in shares of BioMarin Pharmaceutical by 20.5% during the third quarter. Bbva USA now owns 934 shares of the biotechnology company’s stock worth $72,000 after buying an additional 159 shares in the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 0.3% in the second quarter. CIBC Private Wealth Group LLC now owns 62,270 shares of the biotechnology company’s stock worth $5,196,000 after buying an additional 169 shares during the last quarter. Finally, IndexIQ Advisors LLC raised its holdings in BioMarin Pharmaceutical by 5.7% in the third quarter. IndexIQ Advisors LLC now owns 3,151 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 94.15% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Featured Story: Dual Listing

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.